CrownBio Aims For Gold Amid China Precision Medicines Rush

Another week has seen another plethora of deals between Chinese domestic players and global gene sequencing firms. Rising demand for individualized treatments and the rush for cancer immuno-therapies is propelling fast growth for the US-Chinese biotech company Crownbio, says its executive chairman Guo-Liang Yu.

More from China

More from Focus On Asia